Artikel ; Online: 5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
2021 Band 124, Heft 12, Seite(n) 1959–1969
Abstract: Background: Most colorectal cancers (CRC) arise sporadically from precursor lesions: colonic polyps. Polyp resection prevents progression to CRC. Risk of future polyps is proportional to the number and size of polyps detected at screening, allowing ... ...
| Abstract | Background: Most colorectal cancers (CRC) arise sporadically from precursor lesions: colonic polyps. Polyp resection prevents progression to CRC. Risk of future polyps is proportional to the number and size of polyps detected at screening, allowing identification of high-risk individuals who may benefit from effective chemoprophylaxis. We aimed to investigate the potential of 5-aminosalicylic acid (5-ASA), a medication used in the treatment of ulcerative colitis, as a possible preventative agent for sporadic CRC. Methods: Human colorectal adenoma (PC/AA/C1, S/AN/C1 and S/RG/C2), transformed adenoma PC/AA/C1/SB10 and carcinoma cell lines (LS174T and SW620) were treated with 5-ASA. The effect on growth in two- and three-dimensional (3D) culture, β-catenin transcriptional activity and on cancer stemness properties of the cells were investigated. Results: 5-ASA was shown, in vitro, to inhibit the growth of adenoma cells and suppress β-catenin transcriptional activity. Downregulation of β-catenin was found to repress expression of stem cell marker LGR5 (leucine-rich G protein-coupled receptor-5) and functionally suppress stemness in human adenoma and carcinoma cells using 3D models of tumorigenesis. Conclusions: 5-ASA can suppress the cancer stem phenotype in adenoma-derived cells. Affordable and well-tolerated, 5-ASA is an outstanding candidate as a chemoprophylactic medication to reduce the risk of colorectal polyps and CRC in those at high risk. |
|||||
|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Adenoma/drug therapy ; Adenoma/genetics ; Adenoma/pathology ; Adenoma/prevention & control ; Carcinogenesis/drug effects ; Carcinogenesis/genetics ; Carcinogenesis/pathology ; Carcinoma/genetics ; Carcinoma/pathology ; Carcinoma/prevention & control ; Cell Line, Tumor ; Cell Transformation, Neoplastic/drug effects ; Cell Transformation, Neoplastic/genetics ; Chemoprevention/methods ; Colitis, Ulcerative/drug therapy ; Colitis, Ulcerative/genetics ; Colitis, Ulcerative/pathology ; Colorectal Neoplasms/drug therapy ; Colorectal Neoplasms/genetics ; Colorectal Neoplasms/pathology ; Colorectal Neoplasms/prevention & control ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Mesalamine/pharmacology ; Mesalamine/therapeutic use ; Neoplastic Stem Cells/drug effects ; Neoplastic Stem Cells/physiology ; Wnt Signaling Pathway/drug effects ; Wnt Signaling Pathway/genetics | |||||
| Chemische Substanzen | Mesalamine (4Q81I59GXC) | |||||
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2021-03-30 | |||||
| Erscheinungsland | England | |||||
| Dokumenttyp | Journal Article ; Research Support, Non-U.S. Gov't | |||||
| ZDB-ID | 80075-2 | |||||
| ISSN | 1532-1827 ; 0007-0920 | |||||
| ISSN (online) | 1532-1827 | |||||
| ISSN | 0007-0920 | |||||
| DOI | 10.1038/s41416-021-01354-5 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Uh III Zs.142: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.